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OABSTRACT
Background: Artemisinin derivatives are used in
ntimalarial drug combination therapy. Artemisinin
nd piperaquine have recently been proven to be
rospective candidates for combination therapy in
he treatment of uncomplicated Plasmodium falcip-
arum malaria.
Objective: The goal of this study was to evaluate the
relative bioavailability and to characterize the pharma-
cokinetic properties of a new micronized powder for-
mulation of artemisinin against the previous standard
Vietnamese formulation when administered as a single
oral dose or in combination with piperaquine.
Methods: This was a single-center, randomized,
4-sequence, open-label, crossover study conducted in
15 healthy male Vietnamese volunteers under fasting
conditions with a washout period of 3 weeks between
study visits. A single oral dose of 160 or 500 mg of
artemisinin was administered alone or in combination
with piperaquine. Potential adverse events were moni-
tored daily by the clinician and by using laboratory test
results. Frequent blood samples were drawn for 12
hours after dose. Artemisinin was quantified in plasma
using LC-MS/MS. Pharmacokinetic parameters were
computed from the plasma concentration–time profiles
using a noncompartmental analysis method.
Results: Pharmacokinetic parameters Tmax, Cmax,
UC0-, Vd/F, CL/F, and t1/2 (mean [SD]) for the new
ormulation of artemisinin were 1.83 (0.88) hours, 178
97) ng/mL, 504 (210) h  ng/mL, 1270 (780) L, 401
260) L/h, and 2.21 (0.29) hours, respectively. The
644ean percentage of the test/reference formulation ratio
or the logarithmically transformed values of Cmax,
AUC0–last, and AUC0– were 121% (90% CI, 92.5–
158), 122% (90% CI, 101–148), and 120% (90% CI,
98.0–146), respectively.
Conclusions: This single-dose study found that the
dose-normalized Cmax, AUC0–last, and AUC0– mean
eometric differences between the test and reference for-
ulations were relatively small (40%) and will proba-
ly not have a clinical impact in the treatment of malaria
nfections. (Clin Ther. 2011;33:644–654) Crown Copy-
ight © 2011 Published by Elsevier HS Journals, Inc.
Key words: ACT, artemisinin, bioequivalence, ma-
aria, pharmacokinetics, piperaquine.
INTRODUCTION
Malaria remains a major health problem worldwide
due to the emergence of multidrug-resistant Plasmo-
dium falciparum parasite strains.1 In Vietnam and
other parts of Southeast Asia, the parasites have devel-
oped resistance to almost all the drugs available on the
market.2 Resistance to artemisinin derivatives has re-
ently been reported on the Thai-Cambodian border,
s indicated by increased parasite clearance times in
Accepted for publication April 26, 2011.
doi:10.1016/j.clinthera.2011.04.017
0149-2918
Crown Copyright © 2011 Published by Elsevier HS Journals Inc, .
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T.T. Hien et al.patients with falciparum malaria.3–8 However, arte-
isinin derivatives (artemisinin, artesunate, arte-
ether, arteether, and dihydroartemisinin) are still
ery effective, with 5% polymerase chain reaction
PCR)-confirmed parasitologic treatment failures at
ay 28 when treating multidrug-resistant falciparum
trains with artemisinin-based combination therapy
ACT).9–12
Artemisinin monotherapy was registered in Viet-
nam as first-line treatment for a number of years in the
1990s. A major drawback with artemisinin mono-
therapy and its derivatives is the high recrudescence
rate observed in clinical studies (10% recrudescence
rate with 5 days ofmonotherapy).13 The short terminal
1/2 of the artemisinin derivatives (ie, 0.5–2 hours) has
een suggested as the main reason for the resulting low
fficacy when these drugs are used as monotherapy.
he artemisinin derivatives have therefore been used in
ifferent combination treatments to reduce the high
ecrudescence rates observedwithmonotherapy and to
revent the development of parasite drug resistance by
ntroducing another drug with a different mechanism
f action.14–16 ACT is now recommended as first-line
treatment worldwide for uncomplicated falciparum
malaria.17
Artemisinin has not been used to a great extent in
ACTs because of its time-dependent pharmacokinetics
and relatively low bioavailability (30%). Artemisinin
and artemether, but not artesunate or dihydroartemis-
inin, reportedly have a marked ability for enzymatic
autoinduction when administered continuously over
several days.18–23 These time-dependent pharmacoki-
etics can be seen as an increase in the clearance rate
fter repeated oral administration. However, this
harmacokinetic characteristic should be less pro-
ounced if artemisinin were used in a combination
reatment that had a duration of therapy shorter than
hat used in monotherapy. The traditional oral arte-
isinin formulation has a low relative bioavailability
f 30% compared with intramuscular oil suspen-
ion, and very low and erratic concentrations were re-
orted after rectal administration in healthy volun-
eers.24,25 A new formulation has been developed
ontaining smaller drug particles (ie, micronization) to
ncrease the effective surface area after disintegration
nd deaggregation. This change is believed to improve
issolution of oral artemisinin and therefore also the
elative bioavailability.26
May 2011Piperaquine has been used for decades as mono-
therapy and was introduced as a partner drug in com-
bination therapy with artemisinin derivatives during
the 1990s in China.27 The fixed oral combination of
piperaquine and dihydroartemisinin is reportedly well
tolerated (early vomiting, 1.7%) with high efficacy
(PCR-corrected cure rate of 98.7% at day 28) in adults
with uncomplicated malaria.12 This fixed combination
eportedly has a slightly lower efficacy in children
PCR-corrected cure rate of 94.2% at day 28). Toler-
bility and efficacy of a new fixed oral combination of
rtemisinin-piperaquine and the commonly used dihy-
roartemisinin-piperaquine combination have recently
een reported in 103 Vietnamese adult patients with un-
omplicated falciparum malaria.28 In patients receiving
the artemisinin-piperaquine combination, there were no
significant differences (mean [SD]) in parasite clearance
times (43.2 [13.9] vs 36.5 [17.1] hours) or in fever clear-
ance times (24.2 [9.9] vs 22.7 [11.2] hours) when com-
pared with the commonly used dihydroartemisinin-pip-
eraquine combination. Both combinations resulted in a
100% cure rate with no recrudescent malaria at day 28,
but the artemisinin-piperaquine combination resulted in
a lower incidence of gastrointestinal adverse events than
the dihydroartemisinin-piperaquine combination. The
artemisinin-piperaquine combination has a simplified
dosing scheme (2-day therapy) compared with com-
monly used ACTs (3- to 6-day therapy), which may in-
crease patient compliance and consequently the efficacy
of the treatment. However, a shorter treatment regimen
might not be sufficient in some areas and should be used
with caution because it may cause artemisinin resistance
to emergemore quickly. To the best of our knowledge, no
pharmacokinetic information of this novel artemisinin-
piperaquine combination can be found in the interna-
tional published literature.
The main objective of the present study was to deter-
mine if the micronization of artemisinin powder would
increase its oral bioavailability. This hypothesis was ex-
plored by investigating the pharmacokinetics of artemis-
inin in amicronized formulation (micronized artemisinin
powder encapsulated and in a fixed oral combination
with piperaquine in tablet formulation* ) compared with
the reference formulation of previously used standard
Vietnamese formulation (encapsulated artemisinin pow-
der)when administered as a single oral dose. A secondary
*Trademark: Artequick® (Artepharm Co., Ltd., Guangzhou,
China).
645
Clinical Therapeuticsobjective was to investigate the potential influence of pip-
eraquine on artemisinin pharmacokinetics.
SUBJECTS AND METHODS
Study Subjects
Fifteen healthy Vietnamese male volunteers aged 18
to 55 years were enrolled in the study. No female sub-
jects were enrolled to avoid potential risks of adverse
effects on the fetus during early pregnancy. The study
design and potential adverse drug effects were ex-
plained to all volunteers in their own language before
initiation of any study-related procedures. Volunteers
who provided written informed consent were consid-
ered for enrollment. Clinical and laboratory screenings
were performed at the Hospital for Tropical Diseases
inHoChiMinhCity (HTD-HCMC), Vietnam, and the
results evaluated before enrollment. Clinical evalua-
tion and laboratory assessment (full hematology and
biochemistry) were also performed at follow-up 1
week after the last study visit.
A volunteer was ineligible to participate in the study
if any of the following criteria was met: intake of any
antimalarial agent during the previous 3 months, par-
ticipation in an ongoing clinical drug study or within
the last 3 months, involvement in the planning and/or
conduct of the study, inability to comply with study
procedure during the 10 weeks of participation, or in-
tending to donate blood within 6 months after study
start. Healthy volunteers, according to clinical and lab-
oratory screening data, who fulfilled all of the inclusion
but none of the exclusion criteria were enrolled in the
study.
Study Drugs and Design
This was a single-center, single-dose, open-label,
randomized, 4-sequence, crossover study with a
Table I. Sequences of administered study treatment
Visit 1 2 3 4 5 6 7
1 T1 T1 T1 T2 T2 T2 T
2 T2 T3 T4 T1 T1 T3 T
3 T3 T4 T3 T3 T4 T1 T
4 T4 T2 T2 T4 T3 T4 T3-week washout period (ie, 5 artemisinin half-
646lives) between occasions. The study was conducted
at HTD-HCMC. The clinical trial protocol was re-
viewed and supported by the internal Scientific and
Ethical Committee of the HTD-HCMC and Oxford
Tropical Research Ethics Committee (OxTREC 019-
06), University of Oxford, Oxford, United Kingdom.
The volunteers were randomly assigned to 1 of the 24
possible sequences for the 4 treatment groups (Table I).
Group T1 received a single dose of 2 hard gelatin cap-
sules* (size 2), each containing 80 mg of micronized
artemisinin powder (test formulation); group T2 re-
ceived a single dose of 2 hard gelatin capsules, each
containing 80 mg of artemisinin powder (reference
Vietnamese low-dose formulation); group T3 received
a single dose of 2 hard gelatin capsules, each contain-
ing 250 mg of artemisinin powder (reference Vietnam-
ese dose-strength formulation); and group T4 received
a single dose of 2 tablets, each containing 80 mg of
micronized artemisinin (test formulation) and 360 mg
of piperaquine phosphate. A fixed tablet combination
of piperaquine and the reference Vietnamese formula-
tion is not commercially available and could not be
included in this trial.
Micronized artemisinin powder for group T1 was
produced by Guangzhou University of Traditional
Chinese Medicine, Guangzhou, China (batch number:
20030701) and encapsulated by STADA pharmaceu-
tical joint-venture company, Ho Chi Minh City, Viet-
nam (batch number: NC01-20050920). Artemisinin
powder for groups T2 and T3 was produced by Me-
diplantex, Hanoi, Vietnam (batch number: VN 97)
and encapsulated by STADA (batch numbers: NC02-
20050920 and NC03-20050920). The tablets for
group T4 were produced by Artepharm Co., Ltd.,
*Trademark: Coni-Snap® Capsules (Capsugel [Thailand] Co.,
r each subject.
bject
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T.T. Hien et al.Guangzhou, China (batch number: 20050301). The
artemisinin content of filled capsules was analyzed by
the Unit for Pharmacokinetics and Drug Metabolism,
Department of Pharmacology, University of Gothen-
burg, Sweden, using a HPLC method with ultraviolet
detection.29 Capsules were found to contain a mean
(SD) artemisinin content of 85.8 (1.5) mg, 86.7 (0.75)
mg, and 254 (2.6) mg in 9 capsules of groups T1, T2,
and T3, respectively.
Study drug was administered with 200 mL of drink-
ing water after an overnight fast of10 hours, accord-
ing to US Food and Drug Administration (FDA) guide-
lines for bioequivalence studies.30 The volunteers were
asked to continue fasting for 2 hours after drug admin-
istration. Beverages containing caffeine or alcohol
were not allowed on days of drug administration and
blood sampling. Concomitant food intake was previ-
ously reported to have no effect on artemisinin phar-
macokinetics31 and thus not studied further here. Tol-
rability was assessed daily by the clinician during each
tudy occasion (using an adverse-event report form)
nd at the follow-up visit 1 week after last study occa-
ion (using an adverse-event report form and labora-
ory assessment). Adverse events were accessed by us-
ng an open question about potential health problems
uring the study and followed up with a questionnaire
f any health problems had occurred since the last
onsultation.
Blood Sampling
An intravenous indwelling cannula was introduced
and maintained in the antecubital vein and kept for 12
hours during blood sample collection at each study
visit. A blood volume of 0.5 mL was discarded before
sample collection to avoid drug dilution effects. A5-mL
blood sample was drawn into lithium heparin tubes
(Hong Thien My Medical Equipment Joint Stock Co.,
Ho Chi Minh City, Vietnam) before drug administra-
tion (predose) and at the following times after drug
administration (postdose): 0.25, 0.5, 1, 1.5, 2, 2.5, 3,
4, 5, 6, 7, 8, 10, and 12 hours. The same time schedule
was followed for all study visits. Saline solution (0.9%
sodium chloride, 2 mL) was used to flush the lines after
blood collection. Blood samples were immediately cen-
trifuged at 3000g for 10 minutes at 20°C. Plasma were
transferred to cryotubes within 10 minutes after cen-
trifugation and stored directly at –70°C. All samples
were freighted to Thailand on dry ice and analyzed by
the Clinical Pharmacology Laboratory at Mahidol–
May 2011Oxford Tropical Medicine Research Unit (Bangkok,
Thailand).
Drug Analysis
Plasma concentrations of artemisininwere determined
using LC-MS/MS.32 The LC-MS/MS system consisted of
n Agilent 1200 LC system including an autosampler set
t 4°C and a column oven set at 40°C (Agilent Technol-
gies Inc., Santa Clara, California) coupled with an API
000 triple quadrupole mass spectrometer (Applied Bio-
ystems/MDS SCIEX, Foster City, California). The lower
imit of quantitation was set to 1.03 ng/mL, with a limit
f detectionof 0.257ng/mL.Briefly, 50Lof plasmawas
mixed with internal standard (ie, artesunate), and the
sampleswere extracted on a 96-wellElutionHLB solid-
phase extraction plate (Waters Corporation, Milford,
Massachusetts). Three independent quality-control sam-
ples in plasma (2.89, 40.7, and 571 ng/mL) were pre-
pared fresh and analyzed in triplicate in each batch of
extracted plasma samples. All samples were kept on ice
until loaded onto the solid-phase extraction plate. The
extracted samples were injected directly (5 L) into the
C-MS/MS system.
Pharmacokinetic and Statistical Analysis
Individual artemisinin plasma concentration–time
data were evaluated using a noncompartmental analy-
sis approach as implemented inWinNonlin version 5.0
(Pharsight Corporation, Moutainview, California).
AUC0–last values were calculated using the linear trap-
zoidal method for ascending concentrations and the
ogarithmic trapezoidal method for descending con-
entrations.33 Artemisinin exposure was extrapolated
rom AUC0– by Clast/z for each individual subject to
compute total drug exposure. The terminal t1/2 was
stimated by log-linear regression of 5 to 7 observed
oncentrations. Cmax and Tmax concentrations were
aken directly from the observed data. Vd/F and
CL/F were computed individually according to stan-
dard procedures and summarized for each treatment
group. A difference of 50% was assumed to not be
clinically significant, and the study was powered to
detect a minimum difference of 40% in pharmaco-
kinetic parameters (  0.8,   0.05, %CV [intra-
ndividual]  0.3).
Descriptive statistics and ANOVA with a 95% CI
for the regression coefficient were conducted on indi-
vidual logarithmically transformed pharmacokinetic
parameters (ie, AUC0–last, AUC0–last/D, AUC0–,
647
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Clinical TherapeuticsAUC0–/D, Cmax, Cmax/D, Tmax, CL/F, Vd/F, and t1/2),
ere D equaled dose, using Stata version 10 (Stata
orporation, College Station, Texas). The model al-
owed for examining the effects of formulation, se-
uence, and subjects. Average bioequivalence was
valuated according to the FDA’s guidelines for bio-
quivalence.30,34 The criteria for assuming bioequiva-
lence is met if the 90% CI values for geometric mean
ratios of AUC0–, AUC0–last, and Cmax for the test for-
ulation over the reference formulation fall within
0% to 125%. The point estimate of the geometric
ean ratio and the residual variability from the
NOVA were used to calculate the 90% CIs around
he mean to assess bioequivalence. Geometric mean
atios and CIs for dose-normalized (milligram per
ilogram) parameters were also calculated to com-
ensate for different body weights in the studied
opulation.
RESULTS
Artemisinin Pharmacokinetics
Fifteen Vietnamese male volunteers were enrolled
and completed the study. Full demographic character-
istics are given in Table II.
The concentration–time profiles of oral artemisinin
fter different dosages and formulations were well cap-
ured by the applied sampling schedule in these healthy
olunteers (Figures 1 and 2). Individual pharmacoki-
Table II. Demographic data at enrollment for
the 15 healthy Vietnamese male volun-
teers in this 4-sequence crossover study
of artemisinin.*
Parameter
Value, Mean (SD)
[Range]
Age, y 28.1 (8.5) [19–41]
Weight, kg 59.0 (9.3) [43–80]
Height, cm 166 (6.4) [158–180]
Systolic blood pressure,
mm Hg
115 (7.4) [100–130]
Diastolic blood pressure,
mm Hg
64.0 (6.3) [60–80]
Heart rate, beats/min 80.3 (4.2) [70–86]
*Twelve of the 15 volunteers (80%) were smokers.etic parameters in the different treatment periods
648were computed and are summarized inTable III. Mean
(SD) percentages of artemisinin AUC0– extrapolated
from the last observed concentration to infinity were
2.94% (0.70%), 4.37% (7.4%), 4.29% (2.3%), and
2.43% (0.74%) for groups T1, T2, T3 and T4, respec-
tively. All formulations were rapidly absorbed from
the gastrointestinal tract, with measurable plasma
artemisinin concentrations within 15 minutes to 1.5
hours after drug administration (Figure 2). Pooled
data (n  60) from all treatments show that artemis-
inin plasma concentrations peaked at a mean of 1.64
(0.92) hours after dosing and could be quantified in
all patients for up to 12 hours. Artemisinin was rap-
idly eliminated, with a high mean CL/F of 420 (220)
L/h, a short mean t1/2 of 2.23 (0.44) hours, and a
large mean Vd of 1320 (620) L. There was also a
large interindividual variability in artemisinin phar-
macokinetic parameters, with a %CV between 13%
and 65%.
As expected, statistically (P  0.001) higher values
for Cmax, AUC0–last, and AUC0– were seen in the
roup receiving a higher dose (group T3, 500 mg of
rtemisinin) compared with the other groups (groups
1, T2, and T4, 160 mg of artemisinin). However,
ifferences in milligram per kilogram dose-normalized
Figure 1. Mean (SD) plasma concentration–time
curve of artemisinin in 15 healthy Viet-
namese male volunteers in a 4-sequence
crossover study receiving a single oral
dose of 160-mg micronized test arte-
misinin formulation (group T1 ) and
160-mg reference artemisinin formula-
tion (group T2 Œ). Artemisinin concen-
trations are plotted on a log-linear scale
with the base 10.Volume 33 Number 5
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T.T. Hien et al.AUC and Cmax values did not reach statistical signifi-
ance (P 0.05) when artemisininwas administered as
500-mg dose (group T3) compared with a 160-mg
ose (group T2).
The micronized test formulation (group T1) re-
ulted in 25% higher mean AUC and Cmax values com-
ared with the reference formulation (group T2), but it
id not reach statistical significance (P  0.151, P 
0.052, and P  0.086 for Cmax, AUC0–last, and
UC0–, respectively) due to high intraindividual vari-
Figure 2. Individual plasma concentration–time curv
in a 4-sequence crossover study. (A) Gro
containing 80 mg of micronized artemisinin
dose of 2 gelatin capsules, each containin
formulation); (C) Group T3 received a sing
artemisinin powder (reference Vietnamese
single dose of 2 tablets of micronized arte
formulation) and 360 mg of piperaquine
log-linear scale with the base 10.ability. No statistically significant differences were a
May 2011seen in other pharmacokinetic parameters between dif-
ferent treatment groups receiving artemisinin alone
(groups T1, T2, and T3).
The fixed artemisinin-piperaquine tablet formula-
tion (group T4) resulted in a 35% higher mean AUC
and Cmax values compared with the reference formula-
ion (group T2) (P 0.043, P 0.009, and P 0.018
or Cmax, AUC0–last, and AUC0–, respectively). How-
ver, no statistically significant differences in any phar-
acokinetic parameters could be seen when micronized
rtemisinin in 15 healthy Vietnamese male volunteers
received a single dose of 2 gelatin capsules, each
der (test formulation); (B) Group T2 received a single
mg of artemisinin (reference Vietnamese low-dose
se of 2 gelatin capsules, each containing 250 mg of
strength formulation); and (D) Group T4 received a
in powder, each containing 80 mg artemisinin (test
phate. Artemisinin concentrations are plotted on aes of a
up T1
pow
g 80
le do
dose-
misin
phosrtemisinin powder was administered as a co-formulated
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Clinical Therapeuticsfixed oral treatment with piperaquine (group T4) com-
pared with when administered alone (group T1).
Bioequivalence could not be assumed because the
90%CIs for geometric mean ratios of dose-normalized
and non-normalized AUC0–, AUC0–last, and Cmax ex-
tended beyond the stipulated 80% to 125% limit ac-
cording to the FDA guidelines (Table IV). ANOVA
analysis revealed no significant (P  0.18) sequence
effects for the evaluated pharmacokinetic parameters.
Table III. Noncompartmental analysis of artemisinin
single oral dose. All data as mean (SD) [ra
Parameters
T1/New Formulation (160
mg ART)
T2/Standar
(160
Cmax, ng/mL 178 (97) [36.4–421] 132 (35) [
Cmax/D, kg  ng/mL 
mg
64.8 (37) [13.0–171] 49.3 (19) [
Tmax, h 1.83 (0.88) [0.500–3.00] 1.43 (0.84
AUC0–last, ng/mL/h 489 (200) [126–816] 380 (120)
AUC0–last/D, kg  h 
ng/mL  mg
177 (68) [44.8–272] 140 (48) [
AUC0–, ng/mL/h 504 (210) [129–838] 405 (150)
AUC0–/D, kg  h 
ng/mL  mg
182 (71) [46.1–280] 149 (62) [
t1/2, h 2.21 (0.29) [1.54–2.65] 2.27 (0.45
CL/F, L/h 401 (260) [191–1240] 445 (160)
Vd/F, L 1270 (780) [423–3620] 1420 (490)
T1  micronized artemisinin powder (160 mg); T2  standard Vi
artemisinin formulation (500 mg); T4  micronized artemisinin p
formulation; PQ  piperaquine phosphate; D  dose (milligram p
*Significant difference at P  0.05 compared with reference treatm
Table IV. Bioequivalence of artemisinin in 15 health
study. Values are given as geometric mean
Parameter T1/T2 Ratio
Cmax 121% (92.5–158)
Cmax/D 121% (92.5–158)
AUC0–last 122% (101–148)
AUC0–last/D 122% (101–148)
AUC0– 120% (98.0–146)
AUC0–/D 120% (98.0–146)
T1micronized artemisinin powder (160 mg); T2 standa
Vietnamese artemisinin formulation (500 mg); T4  micro
(720 mg) in a fixed tablet formulation; D dose (milligram650Tolerability
All of the volunteers completed the study and no
adverse events were reported by any of the study sub-
jects. No subject vomited after drug administration.
There was a small but significant difference (P 0.05)
etween enrollment and at follow-up in measured
rea, glucose, creatinine clearance, bilirubin, protein,
lobulin, albumin/globulin, magnesium, aspartate
minotransferase level, and leukocyte, basophil, and
T) in 15 healthy Vietnamese male volunteers after a
ulation
T)
T3/Standard Formulation
(500 mg ART)
T4/Fixed Tablets (160 mg
ART  720 mg PQ)
16] 403 (190)* [120–855] 182 (68)* [51.1–303]
08] 46.4 (21) [13.7–92.3] 67.1 (26)* [18.2–102]
0–4.00] 1.94 (1.1) [0.567–5.00] 1.37 (0.72) [0.500–2.50]
661] 1300 (670)* [422–2630] 510 (180)* [170–908]
40] 148 (67) [48.1–263] 186 (63.5)* [60.4–306]
734] 1360 (710)* [436–2730] 523 (190)* [173–935]
98] 155 (71) [49.7–273] 190 (66)* [61.5–315]
–3.49] 2.29 (0.43) [1.52–3.21] 2.24 (0.18) [1.80–2.50]
813] 479 (270) [183–1148] 357 (180)* [171–926]
2430] 1560 (860) [454–3800] 1130 (450)* [554–2420]
se artemisinin formulation (160 mg); T3  standard Vietnamese
(160 mg) and piperaquine phosphate (720 mg) in a fixed tablet
ram).
oup T2) using between-group ANOVA.
tnamese male volunteers in a 4-sequence crossover
s (90% CI).
T3/T2 Ratio T4/T2 Ratio
278% (213–363) 131% (100–171)
89.0% (68.2–116) 131% (100–171)
315% (260–381) 131% (109–159)
101% (83.2–122) 131% (109–159)
313% (256–383) 128% (105–157)
100% (82.0–123) 128% (105–157)
tnamese artemisinin formulation (160 mg); T3 standard
artemisinin powder (160 mg) and piperaquine phosphate
ilogram).(AR
nge].
d Form
mg AR
79.6–2
26.9–1
) [0.50
[192–
68.6–2
[197–
70.1–2
) [1.76
[218–
[910–
etname
owder
er kilog
ent (gry Vie
value
rd Vie
nized
per kVolume 33 Number 5
T.T. Hien et al.lymphocyte counts in some subjects (Table V). The
different values at enrollment and follow-up were in
the normal range and therefore considered revers-
ible, minor, or of no clinical relevance by the study
physician. One subject had abnormally high alanine
aminotransferase levels (120 U/L) at the follow-up
visit 1 week after the last dose occasion. This in-
crease was reversible, and the alanine aminotransfer-
ase level returned to normal 1 week later (ie, 2 weeks
after the last dose). All subjects had normal ECG
results at baseline and at the end of study
Table V. Baseline and follow-up laboratory data
this 4-sequence crossover artemisinin stu
[range].
Variable Pretreatmen
Biochemistry
Urea, mM 3.49 (0.91) [2.4
Glucose, mM 4.46 (0.68) [3.5
Creatinine, M 72.5 (8.9) [54–9
Total bilirubin, M 9.53 (2.7) [5.0–
Total protein, g/L 71.3 (2.1) [68–7
Albumin, g/L 39.7 (1.8) [36–4
Globulin, g/L 31.5 (2.3) [28–3
Albumin/globulin ratio 1.25 (0.14) [1.0
Ferritin, g/L 126 (57) [55–28
Magnesium, mM 1.09 (0.20) [0.8
AST, U/L 20.5 (8.70 [11–3
ALT, U/L 35.3 (18) [11–68
Hematology
Hematocrit, % 46.8 (2.8) [43–5
Hemoglobin, g/dL 15.6 (0.85) [14–
Erythrocytes, 1012/L 5.33 (0.51) [4.8
Reticulocytes, % 0.653 (0.58) [0.1
Thrombocytes, 109/L 252 (51) [150–3
Leukocytes, 109/L 8.49 (1.7) [5.9–
Neutrophils, % 56.4 (7.1) [47–7
Eosinophils, % 5.15 (5.3) [0.87
Basophils, % 0.808 (0.33) [0.2
Monocytes, % 6.96 (1.4) [5.2–
Lymphocytes, % 30.6 (6.3) [19–3
AST  aspartate aminotransferase; ALT  alanine aminotra
*Significant difference at P  0.05 between pretreatment an(follow-up).
May 2011DISCUSSION
Pharmacokinetic profiles of artemisinin revealed higher
drug concentrations after administration of micronized
artemisinin (groups T1 and T4) compared with the refer-
ence formulation (group T2). The higher drug exposure
suggests an increased bioavailability by micronization,
but the dose-normalized Cmax, AUC0–last, and AUC0–
mean geometric differences between micronized arte-
misinin formulations and the reference formulation
were relatively small (40%) and might not be of clin-
ical significance in the treatment of malaria infections.
the 15 healthy Vietnamese male volunteers in
ll parameters are presented as mean values (SD)
Posttreatment P
5.36 (1.5) [2.4–7.2] 0.001*
3.91 (0.35) [3.5–4.4] 0.002*
92.7 (16) [73–115] 0.001*
16.1 (4.0) [9.0–20] 0.001*
77.3 (5.1) [67–82] 0.001*
39.7 (4.2) [30–46] 0.930
37.7 (6.5) [30–47] 0.002*
1.08 (0.19) [0.80–1.4] 0.003*
117 (36) [69–190] 0.520
] 0.896 (0.17) [0.70–1.1] 0.001*
29.1 (16) [19–80] 0.001*
44.7 (25) [15–120] 0.190
47.7 (2.5) [45–53] 0.680
15.6 (0.78) [15–18] 0.770
5.23 (0.49) [4.6–6.1] 0.100
] 0.700 (0.34) [0.10–1.5] 0.520
258 (59) [130–330] 0.360
7.62 (1.5) [5.4–10] 0.015*
53.7 (6.5) [45–63] 0.120
5.34 (3.2) [1.6–13] 0.110
] 1.12 (0.49) [0.23–2.1] 0.018*
7.47 (1.4) [5.3–10] 0.210
32.5 (6.2) [21–43] 0.041*
se.
ttreatment values using a Wilcoxon signed rank test.for
dy. A
t
–5.2)
–6.5]
2]
13]
4]
2]
6]
–1.5]
0]
0–1.5
6]
]
4]
18]
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d posHowever, these results are derived from a single-dose
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Clinical Therapeuticsstudy in healthy Vietnamese volunteers and should not
be directly extrapolated to a population with malaria.
No statistically significant differences in pharmacoki-
netic parameters could be seen when micronized arte-
misinin was administered alone (group T1) compared
with when it was administered in combination with
piperaquine (group T4). This finding suggests that pip-
eraquine should not influence the pharmacokinetic
characteristics of artemisinin when co-administered in
the proposed fixed oral combination. The newmicron-
ized formulations did not meet the FDA criteria for
assuming bioequivalence with the standard Vietnam-
ese powder formulation. No sequence effect could be
seen in this study, which suggests that any potential
autoinduction of artemisinin metabolic capacity had
normalized within 3 weeks after a single dose.
The pharmacokinetics of artemisinin seen in this
study (mean values of CL/F, 7.26 L/h/kg; Vd/F, 22.8
L/kg; and t1/2, 2.23 hours) were in good agreement
ith those reported previously in healthy Vietnamese
ale volunteers after a single oral administration of
rtemisinin (mean values: CL/F, 7.64, 5.10, and 5.38
/h/kg, respectively; Vd/F, 35.9, 19.4, and 16.4 L/kg;
nd t1/2, 2.10, 2.59, and 2.51 hours).
31,35,36 Artemis-
inin pharmacokinetics were comparable to that re-
ported in Vietnamese patients with liver cirrhosis
(Child-Pugh class B37), indicating no altered clearance
n patients with an underlying liver disease.38 Artemis-
inin has previously been reported to display significant
dose-dependent pharmacokinetics in healthy volun-
teers after administration of 3 different doses (250,
500, and 1000 mg).36 Those healthy volunteers re-
orted an increase in the terminal elimination t1/2 and
a decrease in oral clearance with increasing doses, re-
sulting in a nonlinear increase in drug exposure when
normalized for different dose amounts. A similar dose
dependency was observed in patients with malaria.39
This phenomenon was suggested to be a result of sat-
urated first-pass extraction. Dose-dependent pharma-
cokinetics were not seen in the present study, which
may be a consequence of the narrow range of doses
studied here (160 and 500 mg).
Pooled pharmacokinetic data of smokers and non-
smokers from all treatment arms were analyzed to
evaluate the effect of nicotine on pharmacokinetics.
Smokers had a significantly higher (P  0.024) oral
clearance, with a subsequent lower milligram per kilo-
gram dose-normalized drug exposure compared with
nonsmokers. To the best of our knowledge, only 1
652previous study has provided information about the ef-
fect of nicotine on artemisinin pharmacokinetics in
healthy volunteers.40 That study reported similar phar-
acokinetic parameters for the 2 groups. Artemisinin
n vitro metabolism is mediated primarily by cyto-
hrome P450 (CYP) 2B6, with a minor contribution
rom CYP2A6 and CYP3A4.41 In vitro studies have
eported that CYP2A6 is the most important CYP en-
yme in themetabolism of nicotine.42,43 Consequently,
moking should not have any effect on artemisinin
learance or result in a slightly slower clearance due to
ompetitive inhibition of drug-metabolizing enzymes.
owever, there were only 3 nonsmokers of the 15 vol-
nteers in this study, and the nicotine effect on arte-
isinin pharmacokinetics therefore must be confirmed
n larger studies.
Artemisinin is generally a drug with good tolerabil-
ty at therapeutic doses; no adverse events were re-
orted by the subjects in this study. Biochemistry anal-
sis showed small variations over time and a significant
ifference in a few patients at follow-up compared
ith baseline. Six of the 15 volunteers had higher levels
f aspartate aminotransferase at follow-up compared
ith baseline levels. These higher levels were still in the
ormal range and of no clinical significance. No
hanges were seen in alanine aminotransferase levels
xcept in 1 subject who had high levels at follow-up;
hese high levels returned to normal range within
nother week. Previous studies have reported a sig-
ificant but transient increase in liver enzymes for
rtemisinin and dihydroartemisinin.20,44 Values for
hese patients returned to baseline 2 weeks after
he study. The follow-up visit in this study was only
week after treatment, which may explain why the
iochemistry values in some subjects were still
levated.
CONCLUSIONS
This single-dose study of artemisinin found that the
micronized test formulations resulted in a higher drug
exposure compared with the reference formulation,
but this difference was relatively small and will proba-
bly not have a clinical impact in the treatment of ma-
laria infections. All formulations were well tolerated,
and pharmacokinetics were comparable to what has
been reported previously. Further studies are needed to
investigate the pharmacokinetic properties of this for-
mulation in patients with malaria.
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